Poster Session I. - I: Theoretical and Translational Medicine
Dr. Kollarics Réka
ILWSGN
Semmelweis University
+36704517432
kollarics.reka@phd.semmelweis.hu
Transcriptomic Profiling of Infertile Women with Insulin Resistance: Impact of Insulin-sensitizing Therapies on Gene Expression
Réka Kollarics1, Barnabás Bánfi2, Vera Várhegyi1, Dorottya Mária Mudra3, Zsolt Vigassy2, András Gézsi4, Dóra Gerszi5, Miklós Sipos5, Nándor Ács5, Mária Judit Molnár2, Szabolcs Várbíró6,7, Anikó Gál2
1: Doctoral College, Semmelweis University, Budapest, Hungary
2: Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary
3: St. Imre Teaching Hospital, Budapest, Hungary
4: Department of Measurement and Information Systems, Budapest University of Technology and Economics, Budapest, Hungary
5: Department of Obstetrics and Gynecology, Semmelweis University, Hungary
6: Workgroup for Science Management, Doctoral School, Semmelweis University, Budapest, Hungary
7: Department of Obstetrics and Gynecology, University of Szeged, Hungary
Poszter
Poster Session I. - I: Theoretical and Translational Medicine
Hungarian
Theoretical and Translational Medicine
Introduction: Insulin resistance (IR) negatively impacts fertility. IR has a negative effect on the development of oocytes, embryo quality, endometrial receptivity and the implantation of the embryo. Adequate diagnosis and therapy could restore fertility or improve the success rates of assisted reproductive treatments. There is no international consensus on the diagnostic criteria for IR; multiple approaches exist. In 2024, the Hungarian Society of Gynecological Endocrinology (MSZNET) published national recommendations for IR diagnosis using insulin levels measured at 0, 60, 120 minutes during an oral glucose tolerance test. There are several pharmacotherapeutic options for IR, but the exact intracellular mechanisms of these therapies remain unclear.
Aims:This study aimed to examine the transcriptomic effects of different insulin-sensitizing therapies in infertile female patients.
Method: We diagnosed IR patients with MSZNET criteria and created three treatment groups (n=7 each): myo-inositol, alpha-lipoic acid and vitamin supplemented (VS); metformin-treated (MET); and metformin plus GLP-1 receptor agonist-treated (MET_GLP). A healthy control (HC,n=8) group was included. RNA-Seq analysis of peripheral blood samples was performed, followed by differential expression analysis and pathway analysis.
Results: IR patients exhibited a transcriptomic profile characteristic of insulin resistance. In principal component analysis, IR patients clustered together and were well-separated from healthy controls. Differential gene analysis showed excessive downregulation in IR groups. Pathway analysis revealed that glucose and lipid metabolism, insulin signaling and inflammation were the most affected functions. The extent of downregulation was milder in the MET_GLP group compared to the other groups. Pathway analysis showed the involvement of several inflammation-associated pathways in this group.
Conclusion: The IR patients diagnosed with MSZNET IR criteria exhibited an IR-characteristic transcriptomic profile. MSZNET IR criteria show promising diagnostic potential for the early detection of insulin resistance. Based on our preliminary results, combined pharmacotherapy (including myo-inositol, alpha-lipoic acid, metformin and GLP-1 receptor agonist) may shift the transcriptomic profile of IR patients toward that of healthy controls.
Funding: 2024-2.1.1-EKÖP,NFIH_FK_132812
Semmelweis University
Prof. Dr. Szabolcs Várbíró
I do not give consent to the publication of my abstract on the website of the congress.
in doctoral studies before complex exam (PhD)
Szabad
elfogadva
poszter
nem rendelkezett róla
9015
17:00
17:06